Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome

Pediatr Nephrol. 2016 Nov;31(11):2095-101. doi: 10.1007/s00467-016-3400-y. Epub 2016 Jun 4.

Abstract

Background: Prospective studies have established the mycophenolate mofetil (MMF) efficiency in childhood idiopathic nephrotic syndrome (INS) but reports on the long-term outcome are lacking. Moreover, the search for factors influencing its efficiency would be useful to define its place among the other treatments.

Methods: We performed a monocentric retrospective study including 96 children with steroid-dependent INS followed for 4.7 years (median) (IQ 3-6) after the onset of MMF treatment. The characteristics of responder patients (n = 74), as defined by a 50 % decrease of relapse rate and/or a 60 % decrease of steroid dose, and of non-responder patients (n = 22) were compared by univariate analysis and multivariate logistic regression.

Results: Withdrawal of prednisone was achieved in 48/96 patients after a median duration of 18.1 months (IQ 7.8-30.0) of MMF. Only 26/48 patients did not relapse under MMF alone. After MMF was stopped in these patients, only six remained in remission without any treatment at last follow-up. Responders had a shorter time to remission at the first flare (9.5 vs. 15 days, p = 0.02), a shorter disease duration prior to the onset of MMF (22.2 vs. 94.5 months, p = 0.001), and were younger at the MMF initiation (6.7 vs. 10.1 years, p = 0.02) than non-responder patients. The age of MMF initiation was an independent factor associated with efficiency (OR = 0.80, 95 % CI [0.69, 0.93], p < 0.01).

Conclusions: MMF is more efficient in young patients treated early in the disease course. Nevertheless, MMF has no remnant effect while nearly all patients relapsed after withdrawal of the drug.

Keywords: Child; Minimal change disease; Prednisone; Proteinuria; Relapse.

Publication types

  • Observational Study

MeSH terms

  • Age Factors
  • Anti-Inflammatory Agents, Non-Steroidal
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Drug Therapy, Combination / methods
  • Female
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Mycophenolic Acid / therapeutic use*
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / epidemiology
  • Prednisone / therapeutic use*
  • Recurrence
  • Remission Induction / methods
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Withholding Treatment

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Glucocorticoids
  • Immunosuppressive Agents
  • Mycophenolic Acid
  • Prednisone